Recombinant Mouse GM-CSF (carrier-free)

Product Details

Source

Mouse GM-CSF, amino acids Ala18-Lys141 (Accession # NM_009969) was expressed in E. coli.

Molecular Mass

The 125 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 14.2 kDa. The DTT-reduced protein migrates at approximately 13 kDa and the non-reduced protein migrates at approximately 11kDa by SDS-PAGE.

Purity

Purity is >98%, as determined by Coomassie stained SDS-PAGE.

Formulation

0.22 µm filtered protein solution is in 10mM NaH₂PO₄, 150mM NaCl, pH 7.2.

Endotoxin Level

Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.

Concentration

10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.

Activity

The ED₅₀ is <0.05 ng/ml, corresponding to a specific activity >2x10⁷ units/mg.

Application

Bioassay

Recommended Usage

Use when high specific biological activity is required.

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Application References

1. Ahn J, et al. 2012. PNAS. 109:19386. PubMed
2. Verhagen J, et al. 2012. PNAS. 110:E221. PubMed
3. Bretscher P, et al. 2015. EMBO Mol Med. 7:593. PubMed

Product Citations

1. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
2. Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed
3. Chan L, et al. 2022. Cells. 12: . PubMed
4. Teplensky MH, et al. 2023. Nat Biomed Eng. :. PubMed
5. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
6. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
7. Yu H, et al. 2022. Cancer Immunol Res. 10:1095. PubMed
8. Daradoumis J, et al. 2023. Viruses. 15:. PubMed
9. Petenkova A, et al. 2023. Nat Commun. 14:2761. PubMed
10. Rastogi I, et al. 2023. Oncoimmunology. 12:2212550. PubMed
11. Yang N, et al. 2023. Nat Commun. 14:2898. PubMed
12. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
13. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
14. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
15. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
16. Delbridge ARD, et al. 2021. Front Cell Neurosci. 14:592005. PubMed
17. Xia J, et al. 2020. J Immunol. 205:2077. PubMed
18. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
19. Chowdhury D, et al. 2019. Cell Rep. 27:3873. PubMed
20. Jin Z, et al. 2020. NPJ Regen Med. 5:19. PubMed
21. Iwashita H, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
22. Keller CW, et al. 2020. Autophagy. 1:. PubMed
23. Lin W, et al. 2021. Int J Nanomedicine. 16:2775. PubMed
24. Hao Q, et al. 2022. Front Immunol. 13:1011922. PubMed
25. Alban TJ, et al. 2020. Front Immunol. 1.285416667. PubMed
26. Ahn J, et al. 2012. Proc Natl Acad Sci U S A. 109:19386. PubMed
27. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
28. Snell LM, et al. 2018. Immunity. 49:678. PubMed
29. Bretscher P, et al. 2015. EMBO Mol Med. 7:593. PubMed
30. Woo YD, et al. 2020. J Allergy Clin Immunol. . PubMed
31. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
32. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
33. Lajqi T, et al. 2020. Front Immunol. 11:546415. PubMed
34. Ayala M, et al. 2017. J Cancer Res Clin Oncol. 10.1007/s00432-017-2421-7. PubMed
35. Tian Y, et al. 2021. Front Immunol. 12:761345. PubMed
36. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
37. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
38. Gogokhia L, et al. 2019. Cell Host Microbe. 25:285. PubMed
39. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
40. Ayala M, et al. 2017. Breast Cancer Res Treat. 10.1007/s10549-017-4414-2. PubMed
41. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
42. Khan A, et al. 2021. Cell Rep Med. 2:100372. PubMed
43. Moriwaki K, et al. 2021. Mucosal Immunol. Online ahead of print.. PubMed
44. Markworth JF, et al. 2020. JCI Insight. 5:00. PubMed
45. Barrera-Avalos C, et al. 2021. iScience. 24:103520. PubMed
46. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
47. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
48. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
49. Wang Y, et al. 2019. Front Cell Infect Microbiol. 9:286. PubMed

Antigen Details

Structure

cytokine

Distribution

T cells, monocytes/macrophages, fibroblasts, endothelial cells, mast cells

Function

Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans

Interaction

Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts

Ligand/Receptor

Heterodimer GM-CSFR µ subunit (CDw116); β-subunit (CDw131) in common with IL-3R, IL-5R

Bioactivity

Growth/development granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors

Cell Type

Embryonic Stem Cells, Hematopoietic stem and progenitors

Biology Area

Cell Biology, Stem Cells

Molecular Family

Cytokines/Chemokines, Growth Factors

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Demetri G, et al. 1991. Blood 78:2791.
3. Fan D, et al. 1991. In vivo 5:571.
4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.

Gene ID

12981 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

GM-CSF

Specificity Alt (DOES NOT SHOW ON TDS):

GM-CSF

App Abbreviation (DOES NOT SHOW ON TDS):

BA

UniProt

View information about GM-CSF on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Certificate of Analysis